Adjuvant 5-fluorouracil and leucovorin with or without interferon alfa- 2a in colon carcinoma: National surgical adjuvant breast and bowel project protocol C-05

Journal of the National Cancer Institute

Volumn 90, Issue 23, 1998, Pages 1810-1816

  Wolmark, Norman ^a   Bryant, John ^b   Smith, Roy ^a   Grem, Jean ^c   Allegra, Carmen ^c   Hyams, David ^d   Atkins, James ^e   Dimitrov, Nikolay ^f   Oishi, Robert ^g   Prager, David ^h   Fehrenbacher, Louis ⁱ   Romond, Edward ^j   Colangelo, Linda ^a   Fisher, Bernard ^a  

^a NSABP Foundation Inc   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d Allegheny University   (United States)

^e S Eastern Medical Oncology Center   (United States)

^f MICHIGAN STATE UNIVERSITY   (United States)

^g UNIVERSITY OF HAWAII   (United States)

^h LEHIGH VALLEY HOSPITAL   (United States)

ⁱ KAISER PERMANENTE   (United States)

^j UNIVERSITY OF KENTUCKY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; FLUOROURACIL; FOLINIC ACID; RECOMBINANT ALPHA2A INTERFERON;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER STAGING; CLINICAL PROTOCOL; CLINICAL TRIAL; COLON CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL RATE; TREATMENT FAILURE;

EID: 0032477325     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/90.23.1810     Document Type: Article

References (25)

1. Wolmark N, Rockette H, Fisher B, Wickerham DL, Mamounas E. Leucovorin-modulated 5-FU (LV-FU) as adjuvant therapy for primary colon cancer: NSABP C-03 [abstract]. Proc ASCO 1993;12:A578.
2. Wolmark N, Rockette H, Fisher B, Wickerham DL, Redmond C, Fisher ER, et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 1993;11:1879-87.
3. Wadler S, Wersto R, Weinberg V, Thompson D, Schwartz EL. Interaction of fluorouracil and interferon in human colon cancer cell lines: cytotoxic and cytokinetic effects. Cancer Res 1990;50:5735-9.
4. Chu E, Zinn S, Boarman D, Allegra CJ. Interaction of gamma interferon and 5-fluorouracil in the H630 human colon carcinoma cell line. Cancer Res 1990;50:5834-40.
5. Horowitz RW, Hu XP, Schwartz EL, Wadler S. Modulation of 5-fluorouracil by interferon increases the incidence of DNA double-strand breaks in colon carcinoma cells [abstract 1715]. Proc Am Assoc Cancer Res 1995; 36:288.
6. Schwartz EL, Makower D, Wadler S. Thymidine phosphorylase activity mediates the sensitivity of colon carcinoma cells to 5-fluorouracil [abstract]. Proc Annu Meet Am Assoc Cancer Res 1995;36:A2401.
7. Houghton JA, Adkins DA, Rahman A, Houghton PJ. Interaction between 5-fluorouracil, [6RS]leucovorin, and recombination human interferon-alpha 2a in cultured colon adenocarcinoma cells. Cancer Commun 1991; 3:225-31.
8. Stolfi RL, Martin DS. Modulation of chemotherapeutic drug activity with polyribonucleotides or with interferon. J Biol Response Mod 1985;4: 634-9.
9. Ligo M, Chapekar MS, Glazer RI. Synergistic antitumor effect of fluoropyrimidines and polyinosinic-polycytidylic acid against L1210 leukemia. Cancer Res 1985;45:4039-42.
10. Grem JL, Jordan E, Robson ME, Binder RA, Hamilton JM, Steinberg SM, et al. Phase II study of fluorouracil, leucovorin, and interferon alfa-2a in metastatic colorectal carcinoma. J Clin Oncol 1943; 9:1737-45.
11. Schuller J, Czejka MJ, Schernthaner G, Fogl U, Jager W, Micksche M. Influence of interferon alfa-2b with or without folinic acid on pharmacokinetics of fluorouracil. Semin Oncol 1992;19(2 Suppl 3):93-7.
12. Wadler S, Schwartz EL, Goldman M, Lyver A, Rader M, Zimmerman M, et al. Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma. J Clin Oncol 1989;7:1769-75.
13. Wadler S, Lembersky B, Atkins M, Kirkwood J, Petrelli N. Phase II trial of fluorouracil and recombinant interferon alfa-2a in patients with advanced colorectal carcinoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 1991;9:1806-10.
14. Kemeny N, Younes A, Seiter K, Kelsen D, Sammarco P, Adams L, et al. Interferon alpha-2a and 5-fluorouracil for advanced colorectal carcinoma. Assessment of activity and toxicity. Cancer 1990;66:2470-5.
15. Pazdur R, Ajani JA, Patt YZ, Winn R, Jackson D, Shepard B, et al. Phase II study of fluorouracil and recombinant interferon alfa-2a in previously untreated advanced colorectal carcinoma. J Clin Oncol 1991;8:2027-31.
16. Wolmark N, Bryant J, Smith R, Grem J, Hyams DM, Atkins J, et al. The relative efficacy of 5-FU + leucovorin (FU-LV) and 5-FU-LV + Interferon alta-2a (IFN) in patients with Dukes' B and C carcinoma of the colon: first report of NSABP C-05 [abstract]. Proc ASCO 1998;17:255a.
17. Wolmark N, Wieand HS, Rockette HE, Fisher B, Glass A, Lawrence W, et al. The prognostic significance of tumor location and bowel obstruction in Dukes B and colorectal cancer. Findings from the NSABP clinical trials. Ann Surg 1983;198:743-52.
18. Dukes CE. The classification of cancer of the rectum. J Pathol Bacteriol 1932;35:332-9.
19. Zubrod CG, Schneiderman M, Frei E, Brindley C, Gold G, Schnider B, et al. Appraisal of methods for the study of chemotherapy in man: comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide. J Chronic Dis 1960;11:7-33.
20. Pocock SJ. Allocation of patients to treatment in clinical trials. Biometrics 1979;35:183-97.
21. Efron B. Forcing a sequential experiment to be balanced. Biometrika 1972; 58:403-17.
22. Swain SM, Lippman ME, Egan EF, Drake JC, Steinberg SM, Allegra CJ. Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer. J Clin Oncol 1989;7:890-9.
23. Wittes R. Oncologic therapeutics 1989/1990. Philadelphia (PA): Lippincott; 1989. p. 627-34.
24. Wolmark N, Rockette H, Mamounas EP, Jones J, Petrelli N, Atkins J, et al. The relative efficacy of 5-FU + leucovorin (FU-LV), 5-FU + levamisole (FU-LEV), and 5-FU + leucovorin + levamisole (FU-LV-LEV) in patients with Dukes' B and C carcinoma of the colon: first report of NSABP C-04 [abstract 460]. Proc ASCO 1996;15:205.
25. Gail MH. Eligibility exclusions, losses to follow-up, removal of randomized patients, and uncounted events in cancer clinical trials. Cancer Treat Rep 1985;69:1107-13.